FdaApplication
NDA 206038
Identifiers
- fda_app_no: NDA206038
Properties
| Property | Value |
|---|---|
| applicant_name | VERTEX PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2015-07-02 |
Revenue by product
ORKAMBI
| Period | Revenue |
|---|---|
| Q4 2023 | $44.2M* |
| Q3 2023 | $63.0M* |
| Q4 2022 | $110.8M* |
| Q3 2022 | $146.2M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ORKAMBI | IVACAFTOR; LUMACAFTOR | 125MG;100MG | TABLET;ORAL |
| ORKAMBI | IVACAFTOR; LUMACAFTOR | 125MG;200MG | TABLET;ORAL |
2 products